Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026)
Glass House Brands' (GLAS) quarterly Total Non-Current Liabilities came in at $111.9 million in Q1 2026, little changed year-on-year from $111.8 million in Q1 2025, and up 5.08% on a QoQ basis from $106.5 million in Q3 2025.
Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Total Non-Current Liabilities data on file, last reported at $111.9 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities changed 0.09% year-over-year to $111.9 million in Q1 2026; TTM through Mar 2026 was $111.9 million, a 0.09% change from a year earlier, with the FY2024 full-year figure at $234000.0, down 1.68% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $111.9 million, up from $106.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for GLAS reached as high as $31122.5 billion in Q3 2022 and fell as low as $234000.0 in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $2196.7 billion across 5 years, with a median of $112.9 million in 2025.
- Across the five-year window, Total Non-Current Liabilities soared 117558753.43% in 2022 and slumped 100.0% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $241373.0 in 2022, then fell by 1.4% to $238000.0 in 2023, then decreased by 1.68% to $234000.0 in 2024, then jumped by 45396.15% to $106.5 million in 2025, then increased by 5.08% to $111.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $111.9 million in Q1 2026, $106.5 million in Q3 2025, and $114.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 1.86 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 111.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111.87 Mn |
| Sep 30, 2025 | 106.46 Mn |
| Jun 30, 2025 | 114.01 Mn |
| Mar 31, 2025 | 111.77 Mn |
| Dec 31, 2024 | 234,000.00 |
| Sep 30, 2024 | 142.81 Mn |
| Jun 30, 2024 | 152.54 Mn |
| Mar 31, 2024 | 160.38 Mn |
| Dec 31, 2023 | 238,000.00 |
| Sep 30, 2023 | 4,023.83 Bn |
| Jun 30, 2023 | 142.62 Mn |
| Mar 31, 2023 | 132.95 Mn |
| Dec 31, 2022 | 241,373.00 |
| Sep 30, 2022 | 31,122.53 Bn |
| Jun 30, 2022 | 98.40 Mn |
| Mar 31, 2022 | 65.28 Mn |
| Dec 31, 2021 | 104.20 Mn |
| Sep 30, 2021 | 26.47 Mn |
| Mar 31, 2021 | 479.73 Mn |
| Dec 31, 2020 | 456.33 Mn |